Revolution Medicines reports practice-changing trial results for KRAS-targeted pancreatic cancer drug
Daraxonrasib, a small molecule targeting KRAS, produced results described as practice-changing at ASCO 2026, offering a new approach to one of oncology's hardest tumours.
At the 2026 American Society of Clinical Oncology (ASCO) annual meeting, Revolution Medicines presented results for daraxonrasib, a drug designed to inhibit KRAS — a GTPase long considered undruggable due to its smooth, featureless surface. Pancreatic ductal adenocarcinoma is driven by KRAS mutations in approximately 90% of cases, and the absence of effective targeted options has contributed to its persistently poor prognosis.
The trial data, reported by Stat News, were described as practice-changing by observers at the conference. Daraxonrasib is a member of a class of compounds that occupy a switch-II pocket on mutant KRAS, locking the protein in an inactive state. Earlier agents in this class were monospecific for the KRAS G12C variant; daraxonrasib targets a broader range of KRAS mutations relevant to pancreatic cancer.
Full efficacy and safety data were not detailed in the available lede; the peer-reviewed publication or conference abstract should be consulted for primary endpoints, patient numbers, and adverse event profiles. Regulatory and clinical pathway implications remain to be determined. The story was covered by Stat News on 31 May 2026 under a STAT+ paywall; the conference abstract is the recommended primary source for researchers and oncologists.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Researchers at Revolution Medicines have reported encouraging results for a new drug called daraxonrasib, which targets a faulty protein called KRAS that drives most cases of pancreatic cancer. The results were presented at a large cancer conference called ASCO in 2026 and were described by some doctors as potentially changing how this cancer might be treated in future.
KRAS has been difficult to target with medicines for many decades, so findings like these are considered significant by researchers in the field. The drug is still being studied in clinical trials, and it is not yet approved for use as a standard treatment.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-05-31STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug